| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5442 | 2021 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1705 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet, 2021 | 1362 | 2021 |
| Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1086 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 747 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 616 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 344 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil SAC Clemens, PM Folegatti, KRW Emary, LY Weckx, J Ratcliff, S Bibi, ... Nature Communications 12 (1), 1-10, 2021 | 47 | 2021 |
| Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease RE Drury, S Camara, I Chelysheva, S Bibi, K Sanders, S Felle, K Emary, ... Nature Communications 15 (1), 3402, 2024 | | 2024 |
| Improved estimates of COVID-19 correlates of protection, antibody decay and vaccine efficacy waning: a joint modelling approach DJ Phillips, MD Christodoulou, S Feng, AJ Pollard, M Voysey, D Steinsaltz medRxiv, 2024.07. 02.24309776, 2024 | | 2024 |
| Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial LR Williams, KRW Emary, DJ Phillips, J Hay, JPJ Larwood, ... medRxiv, 2024.02. 28.24303505, 2024 | | 2024 |
Merryn VoyseySenior Statistician, University of Oxford在 paediatrics.ox.ac.uk 的电子邮件经过验证
